Polyneuron is a clinical-stage biopharma company developing Antibody-Catch™ antigen-specific polymers designed to selectively eliminate pathological antibodies while leaving the rest of the immune system intact. Its lead candidate, PN-1007, is being developed as a potential treatment for anti-MAG neuropathy and is planned to enter Phase I/IIa clinical development, with patient studies scheduled to begin before the end of 2020. A second program, PN-1018, is being advanced toward clinical trial application (CTA) approval for Guillain-Barré Syndrome and Multifocal Motor Neuropathy. The company also plans to accelerate preclinical development of its Antibody-Catch portfolio in antibody-mediated renal and hematological diseases. Polyneuron was founded in 2014 as a University of Basel spin-off and is headquartered in Stücki Park, Basel, Switzerland. The company recently extended its Series A financing, bringing additional capital to fund these development plans. Polyneuron Pharmaceuticals is a biotech company pioneering the Antibody-Catch™ platform to design injectable, biodegradable high‑molecular‑weight glycopolymers that act as decoys for pathological autoantibodies. Its lead candidate, PN-1007, targets IgM autoantibodies that cause anti‑MAG neuropathy and has obtained orphan drug designation from the European Medicines Agency. The company plans to use its Antibody-Catch™ chemistry to broaden a product portfolio focused on antibody‑mediated autoimmune diseases and is advancing three additional programs through preclinical development. Proceeds from the recent financing will fund a first‑in‑human proof‑of‑concept trial for PN-1007 and support preclinical advancement of the other programs. Polyneuron was founded in 2014 as a University of Basel spin‑off and is headquartered in Basel, Switzerland. Polyneuron Pharmaceuticals develops injectable, biodegradable high‑molecular‑weight glycopolymers (Antibody-Catch™) designed to bind and eliminate disease‑causing autoantibodies while leaving the rest of the immune system intact. Its lead asset, PN-1007, has delivered preclinical proof of principle and the company plans to advance it into clinical development for anti‑MAG neuropathy. The company completed a CHF3.1 million seed financing (following a second tranche) and will use the proceeds to advance PN‑1007 and explore additional applications of the platform. Polyneuron has expanded its team, appointing Gerhard Müller as Chairman and Michael Wacker as Chief Business Officer. It also concluded a key licensing agreement with the University of Basel. Founded in 2014 as a University of Basel spin‑off, the company is headquartered at the Basel Inkubator in Switzerland and plans to begin the next round of fundraising to reach clinical proof of principle. Polyneuron Pharmaceuticals is developing a novel drug class based on its Antibody-Catch® technology to selectively neutralize pathogenic autoantibodies in autoimmune diseases. The approach aims to provide effective treatments while avoiding the broad immunosuppression and serious side effects of current therapies. The company intends to advance Antibody-Catch® toward clinical development and make the technology a clinical reality, according to CEO Dr. Ruben Herrendorff. Polyneuron won the third and final round of the Venture Kick program, receiving CHF 130,000 in funding. The startup is a University of Basel spin-off and was selected for the Swiss national startup team 2015. As part of that program it participated in an entrepreneurial business development trip to Boston and New York.

Total raised

$41M

Funding rounds

4

Latest round

Series A

Latest activity

Sep 2020